Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

Beam Therapeutics Inc (NASDAQ: BEAM) closed the day trading at $20.36 up 2.13% from the previous closing price of $19.94. In other words, the price has increased by $2.13 from its previous closing price. On the day, 1.96 million shares were traded. BEAM stock price reached its highest trading level at $20.37 during the session, while it also had its lowest trading level at $19.355.

Ratios:

For a better understanding of BEAM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.75 and its Current Ratio is at 6.75. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 30 ’25 when FMR LLC sold 48,374 shares for $20.50 per share. The transaction valued at 991,667 led to the insider holds 2,073,665 shares of the business.

Simon Amy sold 876 shares of BEAM for $17,625 on Jul 03 ’25. The Chief Medical Officer now owns 64,864 shares after completing the transaction at $20.12 per share. On Jul 01 ’25, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 374 shares for $16.94 each. As a result, the insider received 6,336 and left with 65,740 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2060164096 and an Enterprise Value of 1005871296. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.18 while its Price-to-Book (P/B) ratio in mrq is 1.96. Its current Enterprise Value per Revenue stands at 16.689 whereas that against EBITDA is -2.372.

Stock Price History:

The Beta on a monthly basis for BEAM is 2.16, which has changed by -0.15567994 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is 7.62%, while the 200-Day Moving Average is calculated to be -6.66%.

Shares Statistics:

Over the past 3-months, BEAM traded about 2.48M shares per day on average, while over the past 10 days, BEAM traded about 3189430 shares per day. A total of 100.76M shares are outstanding, with a floating share count of 91.26M. Insiders hold about 9.79% of the company’s shares, while institutions hold 101.30% stake in the company. Shares short for BEAM as of 1755216000 were 27170958 with a Short Ratio of 10.97, compared to 1752537600 on 23661756. Therefore, it implies a Short% of Shares Outstanding of 27170958 and a Short% of Float of 30.18.

Earnings Estimates

A comprehensive evaluation of Beam Therapeutics Inc (BEAM) is underway, with the input of 10.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.79 and low estimates of -$1.24.

Analysts are recommending an EPS of between -$3.78 and -$4.92 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$4.39, with 13.0 analysts recommending between -$3.01 and -$5.73.

Revenue Estimates

11 analysts predict $13.57M in revenue for the current quarter. It ranges from a high estimate of $25M to a low estimate of $8M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $14.27MFor the next quarter, 11 analysts are estimating revenue of $13.84M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $8M.

A total of 13 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $65.9M, while the lowest revenue estimate was $31.9M, resulting in an average revenue estimate of $46.84M. In the same quarter a year ago, actual revenue was $63.52MBased on 13 analysts’ estimates, the company’s revenue will be $46.83M in the next fiscal year. The high estimate is $110M and the low estimate is $80k.